A Productive Day: Recipharm Completes Two Biologics Deals


CDMO obtains both Vibalogics and Arranta Bio to increase presence in the sector

Recipharm, a global contract development and manufacturing organization (CDMO), has acquired both Vibalogics and Arranta Bio, CDMOs in the virotherapy and advanced therapy spaces respectively.

Specifically, Vibalogics—who recently expanded in both Germany and the US—has been making it presence known in the biopharma industry by providing specialized CDMO services for the manufacture of live viruses and viral vectors including herpes viruses, pox viruses, adenoviruses, and other viral classes for cancer and other applications, in order to support the full product lifecycle of its clients, including commercial supply.

The deal provides Recipharm with know-how when it comes to new biologics modalities, and Recipharm is also able to build on the capabilities acquired through the Arranta Bio buyout, which was announced the same day.

The aforementioned Arranta Bio—whose deal with Recipharm is expected to close by the end of March 2022—has established a strong microbiome platform with fermentation and purification expertise for naturally-derived and engineered bacteria consortia, alongside analytics, proprietary media and cryopreservative formulations. To help combat supply chain obstacles, the company is also advancing the supply of end-to-end mRNA capabilities across drug substance and drug product under one roof.

“ … Arranta is a leading player in its field that we are proud of bringing under the Recipharm umbrella and continue to build in line with our vision of supporting biotechs by providing process development, manufacturing expertise and bold solutions to take their programs from lab to patient,” says Marc Funk, Recipharm’s CEO.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.